The influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease
- First Online:
- Cite this article as:
- Mygind, N.D., Harutyunyan, M.J., Mathiasen, A.B. et al. Inflamm. Res. (2011) 60: 281. doi:10.1007/s00011-010-0266-5
- 156 Downloads
The inflammatory biomarker YKL-40 is elevated and associated with mortality in patients with stable coronary artery disease (CAD). The aim was to investigate the influence of statin treatment and lipid status on serum YKL-40 and Hs-CRP in patients with stable CAD.
Serum YKL-40, HsCRP, total cholesterol, HDL-c, LDL-c and triglycerides levels were measured in 404 statin treated and in 404 matched non-statin treated patients with stable CAD.
YKL-40 was significantly higher in non-statin treated 110 µg/l (median) compared with 65 µg/l in statin treated (p < 0.001). HsCRP was 3.3 mg/l in non-statin treated compared with 2.1 mg/l in statin treated (p < 0.001).
YKL-40 was not related to cholesterol levels for either statin or non-statin treated patients in the univariate analysis. In statin treated patients, HsCRP was related to a high level of total-cholesterol (p = 0.01) and a low level of HDL-c (p < 0.001).
HsCRP, but not YKL-40, is associated with the cholesterol levels in statin treated patients. This indicates that YKL-40 could be a superior prognostic biomarker in patients with stable CAD, since it is independent of changes in cholesterol levels in both statin and non-statin treated patients.